通过诊断依赖性补贴改善青蒿素联合疗法合理使用:肯尼亚西部整群随机对照试验证据
在肯尼亚西部32个社区整群随机对照试验中,将免费疟疾快速诊断检测与诊断依赖性青蒿素联合疗法(ACT)补贴券相结合,可提高发热患者接受疟疾诊断检测的比例和ACT的合理使用率。12个月时干预组检测率提高9个百分点,18个月时合理ACT使用率提高40%。该策略可能改善零售渠道ACT补贴的可持续性。
要点
- 社区健康工作者提供免费疟疾快速诊断检测,阳性者获ACT折扣券,可提高检测率。
- 诊断依赖性补贴使ACT合理使用率在18个月时提高40%。
- 该策略将补贴与确诊挂钩,可能减少零售渠道ACT浪费并提高可持续性。
核心结论
- 诊断依赖性ACT补贴结合社区和私立零售部门干预,可显著提高疟疾诊断检测率和ACT合理使用率。
- 将ACT补贴仅针对疟疾检测阳性者,可能改善零售部门ACT补贴的可持续性并降低成本。
研究设计与样本
- 在肯尼亚西部32个社区整群(人口约16万)开展整群随机对照试验,按1:1随机分配至干预组和对照组。
- 干预组社区健康工作者为1岁以上发热患者提供按需疟疾快速诊断检测,阳性者获得零售药店可兑换的ACT折扣券;对照组接受标准健康教育、预防和转诊服务。
- 在基线、6、12和18个月开展4次基于人群的横断面调查,随机抽取近4周内有发热的家庭成员,采用意向性治疗分析,使用广义估计方程(GEE)并调整性别、年龄、教育和财富。
主要发现
- 2015年7月至2017年5月,共检测32,404人,发放10,870张折扣券;调查7,416名近期发热参与者,其中62.9%(n=4,653)为18岁以下儿童。
- 12个月时,干预组50.5%(n=454)和对照组43.4%(n=389)的近期发热患者接受了疟疾诊断检测(调整风险差=9个百分点,95%CI 2-15,p=0.015;调整风险比=1.20,95%CI 1.05-1.38,p=0.015)。
- 18个月时检测率调整风险比增至1.25(95%CI 1.09-1.44,p=0.005)。
- 干预组ACT合理使用率从基线41.7%(n=279)升至59.6%(n=403),18个月时干预组合理使用率比对照组高40%(调整风险比=1.40,95%CI 1.19-1.64,p<0.001)。
临床怎么用
- 在疟疾流行区零售ACT使用广泛的场景中,可考虑将免费快速诊断检测与诊断依赖性ACT补贴券结合,以提高检测率和合理用药。
- 干预应覆盖社区健康工作者和私立零售药店,形成检测、发券、兑换的闭环。
局限性
- 无法估计干预的长期影响(超过18个月)。
- 无法独立评估免费检测和折扣券各自对检测率提升的贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than half of artemisinin combination therapies (ACTs) consumed globally are dispensed in the retail sector, where diagnostic testing is uncommon, leading to overconsumption and poor targeting. In many malaria-endemic countries, ACTs sold over the counter are available at heavily subsidized prices, further contributing to their misuse. Inappropriate use of ACTs can have serious implications for the spread of drug resistance and leads to poor outcomes for nonmalaria patients treated with incorrect drugs. We evaluated the public health impact of an innovative strategy that targets ACT subsidies to confirmed malaria cases by coupling free diagnostic testing with a diagnosis-dependent ACT subsidy. METHODS AND FINDINGS: We conducted a cluster-randomized controlled trial in 32 community clusters in western Kenya (population approximately 160,000). Eligible clusters had retail outlets selling ACTs and existing community health worker (CHW) programs and were randomly assigned 1:1 to control and intervention arms. In intervention areas, CHWs were available in their villages to perform malaria rapid diagnostic tests (RDTs) on demand for any individual >1 year of age experiencing a malaria-like illness. Malaria RDT-positive individuals received a voucher for a discount on a quality-assured ACT, redeemable at a participating retail medicine outlet. In control areas, CHWs offered a standard package of health education, prevention, and referral services. We conducted 4 population-based surveys-at baseline, 6 months, 12 months, and 18 months-of a random sample of households with fever in the last 4 weeks to evaluate predefined, individual-level outcomes. The primary outcome was uptake of malaria diagnostic testing at 12 months. The main secondary outcome was rational ACT use, defined as the proportion of ACTs used by test-positive individuals. Analyses followed the intention-to-treat principle using generalized estimating equations (GEEs) to account for clustering with prespecified adjustment for gender, age, education, and wealth. All descriptive statistics and regressions were weighted to account for sampling design. Between July 2015 and May 2017, 32,404 participants were tested for malaria, and 10,870 vouchers were issued. A total of 7,416 randomly selected participants with recent fever from all 32 clusters were surveyed. The majority of recent fevers were in children under 18 years (62.9%, n = 4,653). The gender of enrolled participants was balanced in children (49.8%, n = 2,318 boys versus 50.2%, n = 2,335 girls), but more adult women were enrolled than men (78.0%, n = 2,139 versus 22.0%, n = 604). At baseline, 67.6% (n = 1,362) of participants took an ACT for their illness, and 40.3% (n = 810) of all participants took an ACT purchased from a retail outlet. At 12 months, 50.5% (n = 454) in the intervention arm and 43.4% (n = 389) in the control arm had a malaria diagnostic test for their recent fever (adjusted risk difference [RD] = 9 percentage points [pp]; 95% CI 2-15 pp; p = 0.015; adjusted risk ratio [RR] = 1.20; 95% CI 1.05-1.38; p = 0.015). By 18 months, the ARR had increased to 1.25 (95% CI 1.09-1.44; p = 0.005). Rational use of ACTs in the intervention area increased from 41.7% (n = 279) at baseline to 59.6% (n = 403) and was 40% higher in the intervention arm at 18 months (ARR 1.40; 95% CI 1.19-1.64; p < 0.001). While intervention effects increased between 12 and 18 months, we were not able to estimate longer-term impact of the intervention and could not independently evaluate the effects of the free testing and the voucher on uptake of testing. CONCLUSIONS: Diagnosis-dependent ACT subsidies and community-based interventions that include the private sector can have an important impact on diagnostic testing and population-wide rational use of ACTs. Targeting of the ACT subsidy itself to those with a positive malaria diagnostic test may also improve sustainability and reduce the cost of retail-sector ACT subsidies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02461628.
引用
- Prudhomme O'Meara W, Menya D, Laktabai J, et al. Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya. PLoS Med. 2018. PMID: 30016316. doi:10.1371/journal.pmed.1002607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。